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Abstract 
A simple, precise and accurate high performance liquid chromatography 
(HPLC) method was developed for the simultaneous estimation of metformin 
hydrochloride, rosiglitazone maleate, glibenclamide present in multicomponent 
dosage forms. Chromatography was performed on a 25 cm×4.6 mm i.d., 5-μm 
particle, C18 column with 78:22 (v/v) methanol:20 mM potassium dihydrogen 
phosphate buffer as mobile phase at a flow rate of 1.0 ml/min and UV detec-
tion at 238 nm for metformin hydrochloride, rosiglitazone maleate and gliben-
clamide. The total elution time was shorter than 9 min. This method was found 
to be precise and reproducible. The proposed method was successfully 
applied for the analysis of metformin hydrochloride, rosiglitazone maleate, gli-
benclamide as a bulk drug and in pharmaceutical formulation without any inter-
ference from the excipients. 
Keywords: reverse phase high performance liquid chromatography, 
rosiglitazone maleate, metformin hydrochloride, glibenclamide. 
 
 
Currently, the most commonly prescribed medi-
cations for the treatment of non-insulin dependent 
type 2 diabetes mellitus are drugs such as biguani-
des. For example, metformin hydrochloride, 1,1-di-
methylbiguanide hydrochloride (Figure 1a), is an anti-
hyperglycemic agent [1]. 
It improves glucose tolerance in patients with 
type 2 diabetes and reduces both basal and post-
prandial plasma glucose [2]. Sulfonylurea gliben-
clamide (Gly), 1-{4-[2-(5-chloro-2-methoxybenzami-
do)ethyl]benzensulfonyl}-3-cyclohexylurea (Figure 1c), 
is a second generation hypoglycemic agent [3] that 
appears to lower blood glucose by stimulating the 
release of insulin from the pancreas [4-5]. Thiazoli-
dinedione (TZD) derivatives such as rosiglitazone ma-
leate (Rosi), chemically (±)-5-{4-[2-(N-methyl-N(2-py-
ridyl)amino)ethoxy]benzyl}-2,4-dionethiozolidine (Fi-
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gure 1b) [6], are potent new oral antihyperglicemic 
agents that reduce insulin resistance in patients with 
type 2 diabetes by binding to peroxisome proliferator-
activated receptors gamma (PPAR-γ) [7-9]. For many 
patients with type 2 diabetes, monotherapy with an 
oral anti-diabetic agent is not sufficient to reach target 
glycaemic goals and multiple drugs may be neces-
sary to achieve adequate control [10]. The use of 
combination of biguanides, sulfonylureas and TZDs is 
commonly observed in clinical practice. This com-
bination can be achieved by taking each of the drugs 
separately or alternatively fixed formulations have 
been developed. Combinations of Met, Rosi and Gly 
are available commercially as single tablets. Although 
many methods have been reported in literature for the 
estimation of Met [11-28], Rosi [29-37] and Gly [38- 
-43] individually, only a few methods are available for 
the simultaneous estimation of Met and Rosi [44-46], 
Met and Gly [47-50] and Rosi with Gly [51]. However, 
no analytical method has been published for the 
simultaneous analysis of three drugs combinations 
whether in pure forms or in the pharmaceutical pre-
paration, which became the aim of this work. The 
method described is rapid, economical, precise, and S.S. HAVELE, S.R. DHANESHWAR: DETERMINATION OF GLIBENCLAMIDE…  Chem. Ind. Chem. Eng. Q. 20 (1) 39−47 (2014) 
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accurate and can be used for routine analysis of 
tablets. It was validated as per ICH guidelines [52]. 
 
(a) 
 
(b) 
 
(c) 
Figure 1. Chemical structures of a) metformin hydrochloride, 
b) glibenclamide and c) rosiglitazone. 
EXPERIMENTAL 
Materials and methods 
Pharmaceutical grade working standards met-
formin HCl [Met] (batch no. 1997418), rosiglitazone 
maleate [Rosi] (batch no. 758001) and glibenclamide 
[Gly] (batch no. 2022198) were obtained from Ran-
baxy Laboratories, Dewas, India.  
The commercial tablet (brand name: Diabetrol 
3D, Piramal Health Care, batch No. 20605016), label 
claim: 500 mg of Met, 2 mg Rosi and 5 mg of Gly per 
tablet) was purchased in March 2010 from a local 
pharmacy in Pune.  
All chemicals and reagents were of HPLC grade 
and were purchased from Merck Chemicals, Mumbai, 
India. 
Instrumentation 
The LC system consisted of a pump (Jasco PU- 
-1580 intelligent LC pump) with auto injecting facility 
(AS-1555 sampler) programmed at 20 µl capacity per 
injection. The detector consisted of a UV–Vis (Jasco 
UV 1575) model operated at a wavelength of 238 nm. 
The software used was Jasco Borwin version 1.5, LC- 
-Net II/ADC system. The column used was HiQ Sil 
C18HS 250 mm×4.6 mm, 5.0 µm (Kya Technologies 
Corporation). Different mobile phases were tested in 
order to find the best conditions for separation of Met, 
Rosi and Gly. The mobile phase contained 78:22 (v/v) 
methanol:20 mM potassium dihydrogen phosphate 
buffer and the flow rate was maintained at 1.0 ml/min 
UV detection was carried out at 238 nm (Figure 2). 
The mobile phase and samples was filtered using a 
0.45 µm membrane filter. Mobile phase was degas-
sed by ultrasonic vibrations prior to use. All deter-
minations were performed at ambient temperature. 
Standard solutions and calibration graphs for 
chromatographic measurement 
Met, Rosi and Gly were weighed accurately and 
separately transferred to 10 ml volumetric flasks. All 
the drugs were dissolved in HPLC-grade methanol to 
prepare 1000 µg/ml standard stock solutions. Calib-
ration standards at five levels were prepared by 
appropriately weighed and mixed standard solutions 
in the concentration range of 50–250 µg/ml for Met 
and 0.4–2.0 µg/ml for Rosi and 0.6–3.0 µg/ml for Gly. 
Samples were made in triplicate for each concen-
tration and peak areas were plotted against the cor-
responding concentrations to obtain the calibration 
graphs. 
Sample preparation 
For the analysis of tablets, 20 tablets were 
weighed and finely ground in a mortar. The portion 
equivalent to 500 mg of Met, 2 mg of Rosi and 2.5 mg 
of Gly, was transferred in a 25 ml volumetric flask 
separately, 20 ml of methanol was then added, and 
sonication was done for 45 min with swirling. After 
sonication, the volume was made up to the mark with 
the diluent, and mixed well. The solution was filtered 
through Whatman filter paper (#41) then injected into 
the chromatographic system, and analyzed quanti-
tatively. The analysis was repeated six times. The 
possibility of excipients interference with the analysis 
was examined. S.S. HAVELE, S.R. DHANESHWAR: DETERMINATION OF GLIBENCLAMIDE…  Chem. Ind. Chem. Eng. Q. 20 (1) 39−47 (2014) 
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Optimization of HPLC method 
The HPLC procedure was optimized with a view 
to develop a simultaneous assay method for Met, 
Rosi and Gly. The mixed standard stock solution (200 
µg/ml of Met, 0.8 µg/ml of Rosi and 1.0 µg/ml of Gly) 
injected in HPLC. Different ratios of methanol and 
potassium dihydrogen phosphate buffer at different 
pH and molarities were tested.  
Method validation 
The method was validated according to the ICH 
guidelines. The following validation characteristics 
were addressed: linearity, accuracy, precision, and 
specificity, limits of detection and quantitation and 
robustness. 
Linearity and range 
Calibration standards at five levels were pre-
pared by appropriately weighed and mixed standard 
solutions. From the mixed standard stock solution 
(50–250 µg/ml for Met and 0.4–2.0 µg/ml for Rosi and 
0.6–3.0 µg/ml for Gly). Each concentration was 
injected six times into the LC system keeping the 
injection volume constant. The peak areas were plotted 
against the corresponding concentrations to obtain 
the calibration graphs.  
Precision 
Method repeatability was obtained from RSD 
(relative standard deviation, %) by repeating the 
analysis six times for three concentrations in the 
same day for intra-assay precision. The repeatability 
of sample injection and measurement of peak area for 
active compound were expressed in terms of RSD. 
Intermediate precision was assessed by repeating the 
analysis on three different days. The repeatability and 
intermediate precision variation was carried out at 
three different concentration levels (50, 150 and 250 
µg/ml for Met, 0.4, 1.2 and 2 µg/ml for Rosi and 0.6, 
1.8 and 3 µg/ml for Gly). 
Limit of detection and quantification 
In order to estimate the limit of detection (LOD) 
and limit of quantification (LOQ), blank methanol was 
injected 6 times following the method as described in 
the instrumentation Section. The signal-to-noise (S/N) 
ratio was specified as 3:1 for LOD and 10:1 for LOQ. 
The  LOD  and  LOQ were experimentally verified by 
diluting known concentrations of standard solutions of 
Met, Rosi and Gly until the average responses were 
approximately 3 or 10 times the standard deviation 
(SD) of the responses for 6 replicate determinations. 
Robustness 
The robustness was studied by evaluating the 
effect of small but deliberate variations in the chro-
matographic conditions. The conditions studied were 
flow rate (altered by ±0.1 ml/min), mobile phase com-
position (methanol ±2 ml). These chromatographic 
variations were evaluated for resolution between Met, 
Rosi and Gly. 
Solution stability 
To assess the solution stability, three different 
concentrations of (2, 4 and 6 µg/ml) were prepared 
from sample solutions and kept at room temperature 
for 8 days. These solutions were compared with 
freshly prepared standard solutions. 
System suitability 
The system suitability parameters with respect 
to theoretical plates, tailing factor, repeatability and 
resolution between Met, Rosi and Gly peaks were 
defined. 
 
Figure 2. Overlaid UV spectra of metformin HCl rosiglitazone maleate and glibenclamide measured from 200 to 400 nm. S.S. HAVELE, S.R. DHANESHWAR: DETERMINATION OF GLIBENCLAMIDE…  Chem. Ind. Chem. Eng. Q. 20 (1) 39−47 (2014) 
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Specificity 
Extracts of commonly used placebos were 
injected to demonstrate the absence of interference 
with the elution of the Met, Rosi, and Gly. For deter-
mining selectivity of the method, a powder blend of 
typical tablet excipients containing lactose mono-
hydrate, mannitol, maize starch, povidone K30, citric 
acid anhydrous granular, sodium citrate, natural 
lemon and lime flavor and magnesium stearate was 
prepared and analyzed. All chromatograms were 
examined to determine if the compounds of interest 
co-eluted with each other or with any additional 
excipients peaks. 
Accuracy 
Accuracy of the method was carried out by 
applying the method to drug sample to which known 
amounts of Met, Rosi and Gly standard powder cor-
responding to 80, 100 and 120% of label claim had 
been added (standard addition method), mixed, and 
the powder was extracted and analyzed by running 
chromatograms in optimized mobile phase. These 
mixtures were analyzed by the proposed method. The 
experiment was performed in triplicate and recovery 
(%) and RSD were calculated. 
Analysis of marketed formulation 
The marketed formulation was assayed as des-
cribed above. The peak areas were measured at 238 
nm and concentrations in the samples were deter-
mined using multilevel calibration developed on the 
same LC system under the same conditions, and 
analyzed using linear regression as described earlier.  
RESULTS AND DISCUSSION 
Method development and optimization 
The HPLC procedure was optimized with the 
aim of developing a suitable LC method for the anal-
ysis of Met, Rosi and Gly in fixed dose combined 
dosage form. Initially, methanol and water in different 
ratios were tried. However, a broad peak shape was 
obtained for Met, so water was replaced by potassium 
dihydrogen phosphate buffer (20 mM), and mixture of 
methanol and potassium dihydrogen phosphate buffer 
in different ratios were tried. It was found that 
methanol:potassium dihydrogen phosphate buffer (20 
mM) at a ratio of 78:22, v/v, resulted in acceptable 
retention time (tR 2.51 min for Met, 3.90 min for Rosi 
and 8.12 min for Gly), plates, and good resolution for 
Met, Rosi and Gly at a flow rate of 1.0 ml/min (Figure 3). 
Figure 3. Chromatogram of metformin hydrochloride (200 μg/ml), tR: 2.35 min; rosiglitazone maleate (0.8 μg/ml), tR: 3.90 min; 
glibenclamide (1 μg/ml), tR: 8.12 min; measured at 238 nm, mobile phase: methanol/potassium dihydrogen phosphate buffer 
(20 mM) (78/22, v/v). S.S. HAVELE, S.R. DHANESHWAR: DETERMINATION OF GLIBENCLAMIDE…  Chem. Ind. Chem. Eng. Q. 20 (1) 39−47 (2014) 
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Validation 
Linearity 
Linearity was evaluated by analysis of working 
standard solutions of Met, Rosi and Gly of five diffe-
rent concentrations. The range of linearity was from 
50–250 µg/ml for Met, 0.4–2.0 µg/ml for Rosi and 0.6– 
-3.0 µg/ml for Gly. The regression data obtained are 
represented by calibration curves (Figures 4–6). The 
results showed that within the concentration range 
mentioned above, there was an excellent correlation 
between peak area and concentration of each drug 
 
Figure 4. Calibration curve of Met. 
 
Figure 5. Calibration curve of Rosi. 
 
Figure 6. Calibration curve of Gly. S.S. HAVELE, S.R. DHANESHWAR: DETERMINATION OF GLIBENCLAMIDE…  CI&CEQ 20 (0) 000−000 (2014) 
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Precision 
The results of the intra-day and inter-day pre-
cision experiments are given in Table 1. The deve-
loped method was found to be precise, with RSD 
values for intra-day and inter-day precision < 2%, as 
recommended by ICH guidelines. Separation of the 
drugs was found to be similar when analysis was 
performed on different chromatographic systems on 
different days, as shown in Table 1. 
LOD and LOQ 
The LOD and LOQ values were found to be 0.02 
and 0.06 µg/ml for Met, 0.01 and 0.032 µg/ml for Rosi 
and 0.003 and 0.01 µg/ml for Gly (Table 2). 
Table 2. Limit of detection and quantitation  
Compound 
LOD LOQ 
RSD / % 
Met 0.009  0.72 
Rosi 0.55  0.28 
Gly 0.12  0.43 
Specificity 
Extracts of commonly used placebos were 
injected to demonstrate the absence of interference 
with the elution of the drugs. The results demon-
strated that there was no interference from other 
materials in the tablet formulation, thereby confirming 
the specificity of the method (Fig. 7). 
 
 
System suitability 
System suitability parameters such as the num-
ber of theoretical plates, HETP and peak tailing were 
determined. The obtained results are shown in Table 3. 
Robustness of the method 
To ensure the insensitivity of the developed 
HPLC method to minor changes in the experimental 
conditions, it is important to demonstrate its robust-
ness. None of the alterations caused a significant 
change in resolution between Met, Rosi and Gly, 
peak area, RSD, %, tailing factor and theoretical 
plates (Table 4). 
Table 3. Statistical analysis of parameters required for system 
suitability testing of the proposed HPLC method 
Parameter Met  Rosi  Gly 
Theoretical plates  35547.65  3563  3213.85 
Resolution -  3.01  11.99 
Peak asymmetry  1.31  1.35  1.25 
RSD / %  0.32  0.09  0.04 
Solution stability studies 
Three different concentrations 2, 4 and 6 µg/ml 
were prepared from sample solution and stored at 
room temperature for 8 days. They were then injected 
into the HPLC system and no additional peaks were 
found in the chromatogram, indicating the stability of 
Met, Rosi and Gly in the solution (Table 5). 
 
 
Table 1. Repeatability and intermediate precision; n = 6, average of 50, 150 and 250 µg/ml for Met; 0.4, 1.2 and 2 µg/ml for Rosi and 0.6, 
1.8 and 3 µg/ml for Gly 
Compound Intraday  Interday 
Mean % of assay  RSD / %  Mean % of assay  RSD / % 
Met 100.89  1.14  99.89  1.09 
Rosi 100.71  1.03  99.54  0.37 
Gly 100.03  0.51  100.53  0.29 
        
Figure 7. Representative chromatogram obtained for the commonly used excipients. S.S. HAVELE, S.R. DHANESHWAR: DETERMINATION OF GLIBENCLAMIDE…  Chem. Ind. Chem. Eng. Q. 20 (1) 39−47 (2014) 
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Table 5. Stability of drugs in sample solutions; n = 6, average of 
(50, 150 and 250 µg/ml for Met, 0.4, 1.2 and 2 µg/ml for Rosi; 
50, 150 and 250 µg/ml for Met and 0.6, 1.8 and 3 µg/ml for Gly) 
Parameter Met  Rosi  Gly 
RSD / %  0.74  0.04  1.10 
Recovery studies 
Good recoveries of Met, Rosi and Gly were 
obtained at various added concentrations for the tab-
lets (Table 6). 
Analysis of a commercial formulation 
Experimental results of the amount of Met, Rosi 
and Gly in tablets, expressed as a percentage of label 
claims were in good agreement with the label claims, 
thereby suggesting that there is no interference from 
any of the excipients that are normally present in 
tablets. Fixed dose combination tablets were 
analyzed using the proposed procedures (Table 7). 
The summary of validation parameters is listed 
in Table 8. 
 
Table 8. Summary of validation parameters 
Parameter Met  Rosi  Gly 
Linearity range, µg/ml  50-100  0.4-2  0.6-3.0 
Correlation coefficient  0.9997   0.9997  0.9999  
Limit of detection, µg/ml  0.02  0.01  0.003 
Limit of quantitation, µg/ml  0.06  0.03  0.01 
Recovery (n = 6)  100.19  99.50  99.08 
Precision (RSD / %) 
Intraday 
Interday 
1.14 
1.09 
1. 03 
0.37 
0.51 
0.29 
Robustness Robust  Robust  Robust 
CONCLUSION 
The new HPLC method described in this paper 
provides a simple, convenient and reproducible 
approach for the simultaneous identification and 
quantification that can be used to determine 
metformin hydrochloride, rosiglitazone maleate, 
glyburide in routine quality control. 
 
Table 6. Recovery studies (n = 6) 
Label claim  Amount of drug added, %  Total amount, mg  Amount recovered, mg  Recovery, % 
Met 
500 mg 
80 900  899.28  99.92 
100 1000  1008.3  100.83 
120 1100  1098.02  99.82 
Rosi 
2 mg 
80 3.6  3.601  100.05 
100 4 3.97  99.38 
120 4.4 4.35  99.08 
Gly 
2.5 mg 
80 4.5  4.45  98.91 
100 5 4.96    99.32 
120 5.5 5.44    99.03 
Table 7. Applicability of the HPLC method for the analysis of the pharmaceutical formulations 
Sample  Label claim, mg  Drug content, %  RSD / % 
Met 500  100.39  0.08 
Rosi 2  99.38  0.28 
Gly 2.5  99.88  0.14 
Table 4. Robustness testing (n = 6) 
Chromatographic factor 
Level Retention  time,  tR / min  Resolution (Rs) Asymmetry  (As) 
– Met  Rosi  Gly  Met  Rosi  Gly  Met  Rosi  Gly 
Flow rate, ml/min  0.9  2.30  3.78  7.98  0  6.01  2.39  1.13  1.46  1.38 
1.0 2.35  3.90  8.12  0  3.01  11.99  1.31  1.35  1.25 
1.1  2.39  3.70 4.00  0  6.49  2.48 1.01  1.30 1.25 
Methanol content, %  76  2.40  3.99  8.50  0  3.70  12.06  1.70  1.66  1.40 
78 2.35  3.90  8.12  0  3.01  11.99  1.31  1.35  1.25 
80  2.30  3.10 4.08  0  6.09  2.01 1.30  1.34 1.24 
                S.S. HAVELE, S.R. DHANESHWAR: DETERMINATION OF GLIBENCLAMIDE…  Chem. Ind. Chem. Eng. Q. 20 (1) 39−47 (2014) 
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Nomenclature 
Met: Metformin hydrochloride 
Rosi: Rosiglitazone maleate 
Gly: Glibenclamide 
ICH: International Conference on Harmonisation 
HPLC: High Performance Liquid chromatography 
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NAUČNI RAD 
   ODREĐIVANJE GLIBENKLAMIDA, METFORIN- 
-HIDROHLORIDA I ROSIGLITAZON-MALEATA U 
TABLETAMA REVERSNO-FAZNOM 
HROMATOGRAFIJOM POD VISOKIM PRITISKOM 
Razvijena je jednostavna, precizna i tačna HPLC metoda za simultano određivanje 
metformin-hidrohlorida, rosiglitazone-maleata i glibenklamida u multikomponentnim lekov-
itim preparatima. Određivanje je izvedeno na C18 koloni dimenzija 25 cm×4.6 mm i.d., i 
veličina  čestica 5 μm. Kao mobilna faza korišćen je rastvarač metanol:kalijum-dihidro-
genfosfat (20 mM) 78:22 (v/v) sa protokom 1,0 ml/min. Metformin-hidrohlorid, rosiglitazon-
-maleat I glibenklamid su detektovani na 238 nm. Ukupno vreme analize je kraće od 9 min. 
Metoda je precizna i reproduktivna i uspešno je primenjena za određivanje metformin 
hidrohlorida, osiglitazone osigli I glibenklamida u aktivnim supstancama I farmacetskim 
formulacijama bez interferencije sa dodatim ekscipijensima. 
Ključne reči: RP-HPLC, rosiglitazon-maleat, metformin-hidrohlorid, glibenklamid. 
 
 